MedTrace Logo

Childhood Acute Lymphoblastic Leukaemia: Follow-Up

NCT03545659 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2021-09-01

No results posted yet for this study

Summary

Over the past decades, advances in treatment have led to an increasing number of children who survive cancer, resulting in a growing population of childhood cancer survivors. After end of cancer treatment on common protocols survivors are enrolled in non-harmonized follow-up programs with frequent visits and blood samples. However, the evidence for the value of these follow-up programs with respect to the effect on detecting relapse and the effects on overall survival is scarce.

The aim of the study is to give a comprehensive description of the detection mode of relapsed acute lymphoblastic leukaemia (ALL), including symptoms and blood test results. Further, we aim to evaluate if the mode of detection affects survival.

Conditions

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Recurrence

Interventions

OTHER

Mode of relapse/SMN detection

Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henrik Schrøder, Professor · Aarhus University Hospital

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-04
Primary Completion
2020-12-30
Completion
2021-01-20

Countries

  • Denmark
  • Finland
  • Iceland
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545659 on ClinicalTrials.gov